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ences in survival could be identiﬁed apart from the general ﬁnding that 
survivorship decreased as the number of positive stations increased.
In order to reconcile the Naruke and MD-ATS lymph node maps and 
permit analyses of cases with N1 and especially N2 disease to include 
larger number of patients, lymph node stations were grouped together 
into anatomical “zones”. Lymph nodes at levels 1-4 were grouped to-
gether into the “upper zone”, levels 5 and 6 into the “AP zone”, level 7 
into the “subcarinal zone”, levels 8 and 9 into the “lower zone”, levels 
10 and 11 into the “hilar zone”, and levels 12-14 into the “peripheral 
zone”. The appropriateness of grouping lymph node stations into 
“zones” was suggested by exploratory analyses that failed to identify 
signiﬁcant differences in survival in relationship to disease in all of the 
various N1 and N2 lymph node stations in data submitted from Japan, 
or from non-Japanese groups, or both. Signiﬁcant differences in sur-
vival for patients with lymph node metastases conﬁned to a single zone 
were only seen for cases of right-sided tumors with upper or subcarinal 
zone disease compared to peripheral zone metastases. No differences 
in survival were identiﬁed among patients who had single zone N2 
disease. AP zone disease in the absence of N1 metastases was associ-
ated with a better survival in patients with left upper tumors, but similar 
differences in survival were not identiﬁed for right upper lobe tumors 
with right paratracheal nodal metastases.
The potential impact of the number of involved lymph node zones 
on survival was then examined. Three groups were found to have 
signiﬁcantly different survivals: patients who had N1 single zone 
disease, those who had either multiple N1 or single N2 zone metastases 
and those who had multiple N2 lymph node zones involved. These 
prognostically distinct groups suggested that it might be appropriate to 
subdivide the current N staging descriptors into N1a (single N1 zone), 
N1b (multiple N1 zones), N2a (single N2 zones), and N2b (multiple 
N2 zones). In order to determine whether such a revision to the staging 
system should be considered, these additional N categories were ana-
lyzed in conjunction with each T stage category (e.g. T1N1a, T1N1b, 
T1N2a, T1N2b, etc.) rather than across all T stages as was done for all 
of the preceding analyses. However, the number of patients available in 
each of these subsets was too small to yield statistically valid analyses. 
Therefore, on the basis of the available data, we cannot recommend 
altering the current N stage descriptors.
In summary, analyses of clinical and pathological N staging in the 
IASLC database support the continued use of the current N descriptors 
in the lung cancer database. Additional analyses suggest that consolida-
tion of multiple lymph node stations into “zones” and stratiﬁcation of 
patients into 3 groups according to the extent of nodal disease may be 
appropriate and warrant inclusion in future studies.
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Purpose: To analyse all non-lymphatic metastatic components (T4 and 
M1) of the current TNM system of lung cancer with the objective of 
providing suggestions for the next edition of the TNM classiﬁcation for 
lung cancer.
Material and Methods: Data on 100,809 patients were submitted to 
the International Association for the Study of Lung Cancer Interna-
tional Database. 5,592 selected T4M0 and M1 patients fulﬁlled the in-
clusion criteria for the analysis. Speciﬁc categories of clinically staged 
T4 (lesions not continuous with the primary tumor) and M1 cases were 
compared with respect to overall survival using Kaplan-Meier survival 
estimates and comparisons via Cox regression analysis. Relevant ﬁnd-
ings were internally validated by geographic area and type of database, 
and externally validated by the North-American Surveillance, Epidemi-
ology and End Results Registries. 
Results: Median survival for cT4M0 with malignant pleural effusion 
was signiﬁcantly worse than that of other cT4M0 patients (8 months vs. 
13 months) and was more comparable to M1 cases with metastases to 
the lung only (10 months). M1 cases with metastases outside the lung/
pleura had a signiﬁcantly poorer prognosis than those with metastases 
conﬁned to the lung, with a median survival of 6 months.
Conclusions: Revisions to the TNM classiﬁcation system for lung 
cancer should include grouping cases with malignant pleural effusions 
and cases with nodules in the contralateral lung in the M1a category, 
and cases with distant metastases should be designated M1b. In addi-
tion, cases with nodule(s) in the ipsilateral lung (non-primary lobe), 
currently staged M1, should be reclassiﬁed as T4M0, in accordance 
with the recommendations of T descriptor sub-committee of the IASLC 
International Staging committee.
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Potential a priori useful prognostic variables for survival of patients 
presenting with lung cancer, as determined according to the series anal-
yses reported in the literature, include in addition to the TNM stage:
• Tumour characteristics : localization of metastatic sites : brain, liver, 
adrenals, bone, lung; number of metastatic sites; pleural effusion; 
type of lesions (assessable, measurable); tumour size and volume; 
histology : non-small cell lung cancer (NSCLC) or small cell lung 
cancer (SCLC); squamous cell carcinoma versus adenocarcinoma 
versus large cell carcinoma ...; neuroendocrine tumours; tumour 
differentiation and grade ; lymphatic and blood vessel invasion; 
symptoms; ﬂuorodeoxyglucose positron emission tomography 
(FDG-PET) scan
• Patients characteristics : age; sex; performance status (PS); weight 
loss; smoking history; race; comorbidities (Charslon’s index, 
Colinet’s simpliﬁed comorbidity score)
• Laboratory parameters : serum bilirubin; serum calcium ; serum 
sodium ; serum creatinine; haemoglobinemia; leucocytosis; neutro-
